Parkinson's Archives

Prothena, Parkinsons Disease, neurons, neurological diseases

News and Trends 15 Sep 2022

Neuron23 and QIAGEN to collaborate on diagnostic for novel Parkinson’s drug

Neuron23 Inc. and QIAGEN are to collaborate to develop a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease. Under the agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson’s disease patients to a LRRK2 inhibitor. The […]

September 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Collaboration to explore gene therapy products for neurodegenerative disorders

Coave Therapeutics is collaborating with the Institute of Neurodegenerative Diseases (IMN) of Bordeaux to develop gene therapy proteins targeting protein degradation in neurodegenerative disorders. The IMN is a joint research unit associating the University of Bordeaux and the French National Centre of Scientific Research (CNRS) developing gene therapy programs targeting protein degradation in neurodegenerative disorders. […]

September 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 6 Sep 2022

IRLAB’s partner Ipsen starts mesdopetam clinical studies

IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, says its partner, Ipsen, has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan. These are standard clinical pharmacokinetic studies that will run in parallel to the phase IIb study with […]

September 6, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Parkinson’s Foundation and Parkinson’s UK partner to drive drug development

The Parkinson’s Foundation and Parkinson’s UK, which funds research and provides support for people with Parkinson’s disease (PD), have announced a new international strategic partnership to boost investment in research on new treatments for PD, which affects 10 million people worldwide. Over the next three years, the Parkinson’s Foundation will invest a minimum of $3 […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 30 Jun 2022

NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders

A neuroscience company targeting mitochondrial dysfunction has teamed up with an organization developing small molecule disease-modifying medicines for the treatment for chronic neurogenerative disorders. Domainex, an integrated medicines research services partner has been chosen by neuroscience company, NRG Therapeutics, and will be providing fully integrated lead optimization services including assay biology and medicinal computational chemistry. […]

June 30, 2022 - 3 minutesmins - By Liza Laws

News and Trends 10 Jun 2022

Expansion into Europe for BlueRock Therapeutics

BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has established a new site for cell therapy innovation on Bayer’s campus in Berlin, Germany. The move comes as part of the company’s growth strategy. A multidisciplinary BlueRock team will be set up during 2022 to provide clinical development and operational […]

June 10, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 May 2022

Award to help NRG Therapeutics develop new Parkinson’s and Motor Neuron Disease treatments

UK neuroscience company NRG Therapeutics Ltd has received a Biomedical Catalyst (BMC) award to fund preclinical development of its small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders. The £2.68M ($5.8M) early-stage BMC award part-funded by the government-backed agency Innovate UK will support a […]

May 31, 2022 - 3 minutesmins - By Jim Cornall

Discovering New Therapeutic Targets for Alzheimer’s Disease

Effective therapies for neurodegenerative diseases like Alzheimer’s are urgently needed. But developing new drugs is difficult, time-consuming, and expensive, with a high risk of failure. Strategic partnerships can help biotech companies manage costs and access the latest technologies to drive innovation and advance novel therapy ideas. A serious unmet medical need Finding treatments for neurodegenerative […]

September 22, 2021 - 7 minutesmins - By Julia Kaiser

News and Trends 12 Aug 2021

European Biotechs Fire up Deals to Develop Parkinson’s Treatments

Last month, European biotechs Ipsen and AC Immune announced multi-million euro deals to acquire or license treatments for Parkinson’s disease. For some experts, this increasing interest in the brain disease with the fastest growing prevalence is long overdue. In July, Swiss company AC Immune bought assets and intellectual property for investigational Parkinson’s vaccines valued at […]

August 12, 2021 - 4 minutesmins - By Anita Chakraverty

In Depth 22 Mar 2021

Can Immunotherapy Offer Hope for Parkinson’s Sufferers?

Despite decades of research, effective treatments for Parkinson’s disease are proving elusive. Could immunotherapy finally provide a solution? More than seven million people worldwide are currently living with Parkinson’s disease, an incurable neurodegenerative disorder. Current treatment options are limited as they only attempt to mask the symptoms rather than address the cause. But there is […]

March 22, 2021 - 5 minutesmins - By David Cox

parkinsons disease treefrog therapeutics cell therapy

News and Trends 9 Jun 2020

French Manufacturing Plant Launches to Make Cell Therapy Cheap and Scalable

The Bordeaux-based company Treefrog Therapeutics has opened an industrial demonstration plant with the aim of producing cell therapies 10 times more efficiently than with current technology. The €2M plant occupies an area around a fifth of the size of a football field and is expected to produce 80 billion cells per year when it reaches […]

June 9, 2020 - 4 minutesmins - By Jonathan Smith

More News! 27 Jun 2019

German Biotech Will Target Parkinsonian Disorders with €12M Series A

Modag has developed a candidate drug targeting the neurodegenerative disease multiple system atrophy, which it plans to take to the clinic with €12M in Series A funds. Multiple system atrophy is a rare disorder, with similar symptoms to Parkinson’s disease, that is caused by breakdown of neurons in parts of the brain. The German biotech’s […]

June 27, 2019 - 2 minutesmins - By Helen Albert

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Parkinson’s

Neuron23 and QIAGEN to collaborate on diagnostic for novel Parkinson’s drug

Collaboration to explore gene therapy products for neurodegenerative disorders

IRLAB’s partner Ipsen starts mesdopetam clinical studies

Parkinson’s Foundation and Parkinson’s UK partner to drive drug development

NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders

Expansion into Europe for BlueRock Therapeutics

Award to help NRG Therapeutics develop new Parkinson’s and Motor Neuron Disease treatments

Discovering New Therapeutic Targets for Alzheimer’s Disease

European Biotechs Fire up Deals to Develop Parkinson’s Treatments

Can Immunotherapy Offer Hope for Parkinson’s Sufferers?

French Manufacturing Plant Launches to Make Cell Therapy Cheap and Scalable

German Biotech Will Target Parkinsonian Disorders with €12M Series A

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!